Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?

Bear, Adham S; Morgan, Richard A; Cornetta, Kenneth; June, Carl H; Binder-Scholl, Gwendolyn; Dudley, Mark E; Feldman, Steven A; Rosenberg, Steven A; Shurtleff, Sheila A; Rooney, Cliona M; Heslop, Helen E; Dotti, Gianpietro

Bear, Adham S; Morgan, Richard A; Cornetta, Kenneth; June, Carl H; Binder-Scholl, Gwendolyn; Dudley, Mark E; Feldman, Steven A; Rosenberg, Steven A; Shurtleff, Sheila A; Rooney, Cliona M; Heslop, Helen E; Dotti, Gianpietro.

Affiliation

Bear AS; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and The Methodist Hospital, Houston, Texas 77030, USA.

Mol Ther ; 20(2): 246-9, 2012 Feb.

Article in En | MEDLINE | ID: mdl-22297819

Subject(s)

Genetic Therapy/adverse effects; Genetic Vectors/genetics; Retroviridae/genetics; T-Lymphocytes/metabolism; Virus Replication/genetics; Animals; Cell Line; Clinical Trials as Topic; Humans; Retroviridae/physiology; Toxicity Tests/economics; Toxicity Tests/standards; Transduction, Genetic

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Retroviridae / Virus Replication / T-Lymphocytes / Genetic Therapy / Genetic Vectors Limits: Animals / Humans Language: En Journal: Mol Ther Journal subject: BIOLOGIA MOLECULAR / TERAPEUTICA Year: 2012 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google